Best for Longevity
Best ALA for Longevity
Top 30 products ranked · Reviewed May 2026 · 300–600 mg clinical dose
Why ALA for Longevity
ALA plays a supporting role in longevity. Alpha-lipoic acid is a sulfur-containing compound that functions as a cofactor for mitochondrial enzymes and is both water- and fat-soluble, giving it unique antioxidant versatility. It regenerates other antioxidants (vitamins C, E, glutathione, CoQ10).
What dose to look for
Clinical studies typically use 300–600 mg of ala. Most studies use 300–600 mg/day of racemic ALA. R-lipoic acid (the natural form) is more bioavailable and used at lower doses (100–300 mg). Doses up to 1200 mg/day used in diabetic neuropathy research. Products below this range may not deliver meaningful results.
What the research says
ALA has strong clinical evidence for longevity benefits. Strong clinical data for diabetic neuropathy and glucose metabolism across multiple trials Learn more
Clinical research on Alpha-Lipoic Acid (R-ALA)
LOW — mechanism only, no category RCTs · 600 mg/day racemic (~300 mg/day R-ALA equivalent) — trial-anchored dose from diabetic-neuropathy studies, not validated for any longevity or cellular-aging endpoint
- •No human RCTs test alpha-lipoic acid against any cellular-aging, senescence, NAD+, or longevity endpoint. The nutrient's own verdict is explicit: anti-aging and general antioxidant claims 'have no good RCT support.' All eight of its logged trials target diabetic neuropathy, glycemic control, or body weight — not cellular healthspan.
- •The category rationale is mechanistic only: ALA acts as a mitochondrial cofactor for the pyruvate dehydrogenase complex, scavenges reactive oxygen species, regenerates other antioxidants (glutathione, vitamins C and E), and chelates redox-active metals. This is a plausible oxidative-stress mechanism, but mechanistic and in-vitro signals do not support clinical longevity claims in humans.
- •The closest human data sit one category away: a 2012 meta-analysis pooled 15 RCTs of ALA for diabetic peripheral neuropathy (an oxidative-stress-driven condition) and reported improved nerve conduction velocity and symptom scores — but this is a disease-specific nerve outcome in diabetics, driven largely by short IV-dosed trials, not a cellular-aging or mitochondrial endpoint in healthy older adults. Do not extrapolate. PubMed